Viewing Study NCT06920251

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:48 PM
Ignite Modification Date: 2026-01-13 @ 7:54 AM
Study NCT ID: NCT06920251
Status: RECRUITING
Last Update Posted: 2025-12-03
First Post: 2025-03-26
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Sponsor: Seoul National University Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed Refractory Multiple Myeloma (RRMM) View
Keywords: